Primary Systemic Amyloidosis clinical trials at UC Health
1 research study open to eligible people
open to eligible people ages 18 years and up
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.
at UC Davis UC Irvine